4-Hydroxy-7-[(2-methoxyphenyl)amino]naphthalene-2-sulfonic acid | 6271-11-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-Hydroxy-7-[(2-methoxyphenyl)amino]naphthalene-2-sulfonic acid
• 英文别名: 4-hydroxy-7-(2-methoxyanilino)naphthalene-2-sulfonic acid
• CAS: 6271-11-0
• 化学式: C₁₇H₁₅NO₅S
• 分子量: 345.4
• InChiKey: XWZHIFXGDVIKDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Methods and compositions for the inhibition of Pin1
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10413548B2

  公开（公告）日：2019-09-17

  The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.

  本发明的特点是抑制 Pin1 蛋白的组合物和方法，以及治疗以 Pin1 水平升高为特征的疾病。
• Arsenic trioxide for treatment of PIN1-associated disorders
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10980835B2

  公开（公告）日：2021-04-20

  The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.

  本发明涉及用三氧化二砷治疗Pin1相关疾病（例如，以Pin1活性升高为特征的疾病），可选择与维甲酸化合物联合使用。Pin1相关疾病可包括与Pin1活性异常水平相关的增殖性疾病（如癌症）、炎症和自身免疫性疾病等。
• Methods and compositions for the inhibition of PIN1
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US11129835B2

  公开（公告）日：2021-09-28

  The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.

  本发明的特点是抑制 Pin1 蛋白的组合物和方法，以及治疗以 Pin1 水平升高为特征的疾病。
• METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US20150133442A1

  公开（公告）日：2015-05-14

  The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
• ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US20180153934A1

  公开（公告）日：2018-06-07

  The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.